05 Feb 2018

Dr. Dot Colagiovanni Featured on This Week’s Cannabis Economy Podcast

Dr. Dot Colagiovanni Featured on This Week’s Cannabis Economy Podcast

Next Frontier’s Vice President of Product Development, Dr. Dot Colagiovanni was interviewed for this week’s Cannabis Economy podcast, hosted by Seth Adler.


A summary of the segment is provided below, and the full interview is available on the Cannabis Economy website: http://www.canneconomy.com 


Dr. Dot Colagiovanni joins us and shares that she’s got a PhD in toxicology, which she put to use in the biotech industry for 20 years until she became disillusioned with the FDA working slowly but also hedge funds coming in to biotech and driving decision making as opposed to the science. She wanted to bring medicine to market sooner at the same time as her son had to have a liver transplant. During the wait to find a liver, Dot wanted to be present and so she and she alone self medicated with cannabis after her son went to bed. She had never utilized cannabis medically and she says, cannabis helped her cope. She put two and two together and realized the cannabis industry was where she needed to be.


Hosted by Seth Adler, Cannabis Economy is a real-time history of legal cannabis. We chronicle how personal and industry histories have combined to provide our current reality. Who you are informs what you do. Business is personal.

16 Jan 2018

CFN Media Interviews Next Frontier Biosciences

CFN Media Interviews Next Frontier Biosciences

Research and development into medicinal cannabis has grown by leaps and bounds since the rise of legalization. Next Frontier Biosciences is a biotech firm specializing in the creation of best-in-class purified cannabinoid products specifically designed for the medical markets. Using advanced formulation sciences, the company has already introduced a line of sublinguals, nasal mists, and topicals to the cannabis industry. The Verra Wellness line of products is meant to help new consumers ease into cannabis consumption.


CFN Media recently sat down with Next Frontier Co-Founder and CEO, Marc Graboyes, and Vice President, Pharmaceutical Development, Dorothy “Dot” Colagiovanni, Ph.D. , to learn more about the company’s impressive scientific and research-based approach to cannabis product development.


Rachelle Gordon: What is the history of Next Frontier Biosciences?


Marc Graboyes: Myself, along with my partner Paul Johnson, came together to bring advanced sciences to the cannabis industry; we recruited Dot a short time later before we founded Next Frontier in late 2014. We’ve been actively pursuing formulation sciences and product development for the last two and half years to the point where we are now launching our first line of branded products in Colorado this week.


The name of the line is Verra Wellness, which offers purified cannabinoid products for nasal, sublingual, and topical delivery. We’re really excited to launch in Colorado, and then we’ll be pursuing a multi-state expansion strategy with the goal of licensing our propriety formulations and brand identity in multiple states with a focus on California, Oregon, Washington and Nevada.


We are a group of former biotech executives and research scientists who are bringing advanced formulation sciences to the cannabis industry, working with highly purified cannabinoids and scientifically formulating them for improved delivery. We also are an IP holding company and provide brand management.


RG: What is the benefit of Verra Wellness for the end user?


MG: It’s really the fact that the Verra Wellness purified cannabinoid products are so accurate, consistent, and convenient for microdosing, which allows you to achieve the maximum benefit with the minimum dose. We are providing alternative modes of administration for people who don’t want to smoke, vaporize, or eat cannabis products and we like think the products are kind of sexy. They look great, they’re very convenient, and discreet. If you have a soccer mom that just wants to throw a discreet container in her purse that’s pretty easy to do and doesn’t have that sort of stigma associated with smoking or vaporizing.


Dot Colagiovanni: Our tag line is Derived From Truth. The word Verra comes from the French word meaning derived from truth; this is who we are philosophically. We’re coming to this industry trying to be transparent, and upfront with what we’re doing, all while providing really good science and hard data to take the industry to the next level of that credibility.


RG: What else sets Next Frontier apart from potential competitors?


DC: First of all, we’ve developed consistent, reliable, and safe products that we think will benefit consumers. We didn’t come into it like a lot of people do having already been in the industry or come into it from business standpoint. We took a different approach: coming from the science side of it. We felt that’s where our strength is and we all know how to develop drugs; the difference between making a cannabis product and making a pharmaceutical product isn’t that big. Our team has the expertise.


MG: Another thing that really sets us apart is our target audience/market. We’re not going after the traditional cannabis consumer who is simply looking to “get high.” We’re looking to provide much more of a therapeutic wellness benefit, whether it’s on the recreational or medical side. We like to target those who were previously scared by the stigma of cannabis, making it a lot more approachable while providing great branding where people would be excited and proud to be carrying our products with them. We are trying to bring new people into the market.

See the full interview on the CannabisFN website.

11 Jan 2018

5280: Denver’s Digital Health Boom

5280: Denver’s Digital Health Boom

The latest issue of 5280 Magazine features Colorado marijuana companies harnessing cutting-edge tech to deliver more personalized treatment to patients all over the world–and Next Frontier Biosciences was included! View the feature below and on the 5280 website.


The Problem: Inconsistent doses of MJ

The Solution: Some Coloradans consume marijuana as a substitute for antidepressants. It’s called “microdosing”—taking 0.3 to just under five milligrams as opposed to the state-recommended dose of 10 milligrams for recreational use. The issue, whether you smoke or eat the pot, is measuring out a consistent dose. Not only do Next Frontier scientists engineer marijuana that delivers the same level of THC every time, but the Denver company’s Verra Wellness brand also packages the cannabis in nasal mist and sublingual (under the tongue) spray canisters. Both of those areas absorb THC quickly, ensuring you don’t overindulge due to a delayed response.

10 Jan 2018

Cannabis Business Executive: 2017 Recap and New Year’s Wishes from Cannabis Industry Leaders

To kick off the new year, Cannabis Business Executive asked several cannabis industry pioneers and leaders to share their wishes and predictions for the industry in 2018. Marc Graboyes, Co-Founder and CEO of Next Frontier Biosciences was among those featured in the article.


His predictions and wishes for 2018 are below:


“For 2018, I’m excited to see the cannabis industry continue embracing the power of scientific research and development to develop safer and more effective cannabinoid based products. I expect the industry to more deeply explore the benefits of cannabinoid purification and scientific formulation in the quest for cleaner and more well-characterized products that are free from the harmful effects associated with smoking. As we educate the public about the therapeutic benefits of cannabinoids, we will see patients trading in their dangerous opioids for safer cannabinoid-based products. With these improvements, the health and wellness communities will take notice of the important work the cannabis industry is doing, allowing us to expand our reach and spread the word to more individuals about how cannabis-based products can help improve their lives.


In the coming year, we will see the industry place a stronger emphasis on research, promoting a scientific evidence-based approach that will allow us to learn more about the vast potential of the plant. Contributing to the growing body of literature on cannabis will help us build and expand upon our current knowledge while informing our future efforts. As an industry, we will continue advocating for sensible legislation so that we can turn back the damage wreaked by prohibition and eventually overcome the negative stigma surrounding cannabis altogether. In turn, we will foster an academic dialogue that elevates the industry to the highest standards of excellence and cultivate a positive nationwide discourse.”


To read the full article, visit Cannabis Business Executive.

03 Jan 2018

Dr. Dot Colagiovanni Named Among Top Ten Influential Women to Meet at the NCIA Seed to Sale Show

Dr. Dot Colagiovanni Named Among Top Ten Influential Women to Meet at the NCIA Seed to Sale Show

Congratulations to Next Frontier’s Vice President of Pharmaceutical Development, Dr. Dot Colagiovanni, who has been named one of the top ten most influential women to meet at this year’s NCIA Seed to Sale Show, taking place in Denver on February 7th and 8th.


Dr. Colagiovanni will be presenting at the conference on February 7th from 11:15 am-12:30 pm in a session titled “Controlling Terpenes and Cannabinoids in Flower and Extract.” For more details, visit the 2018 NCIA Seed to Sale Show website.

07 Dec 2017

Cannabis Industry Journal: New Drug Delivery Mechanisms For Cannabis Products

Cannabis Industry Journal: New Drug Delivery Mechanisms For Cannabis Products

Next Frontier Biosciences announced the launch of their new product line, Verra Wellness, in the Colorado market this week. The products are designed with relatively new concepts for the cannabis market, including nasal, sublingual and topical administration.


Co-founded by biotech executives Marc Graboyes and Dr. Paul Johnson, Ph.D, Next Frontier Biosciences is developing this product line with three formulations, each with a different ratio of THC and CBD. According to a press release, Next Frontier Biosciences is focused on developing cannabis products with these new drug delivery methods, and even offering a microdosing option.


“We believe that leveraging science and research is the key to optimizing product development,” says Dr. Johnson, one of the co-founders. “With the introduction of our Verra Wellness line of products, we are reshaping the cannabis industry by offering trusted products that provide uniform composition, formulation and dosing in highly consistent modes of administration.”


Read more about Next Frontier’s novel delivery technologies–including the world’s first cannabis nasal mist–on Cannabis Industry Journal.

06 Dec 2017

Cannabis Business Executive: Next Frontier Biosciences Launches Revolutionary Product Line Verra Wellness

Cannabis Business Executive: Next Frontier Biosciences Launches Revolutionary Product Line Verra Wellness

Next Frontier Biosciences announced today the launch of its Verra Wellness line of purified cannabinoid products into the medical and adult-use marijuana markets in Colorado. The Verra Wellness products are scientifically formulated for improved delivery via nasal, sublingual and topical administration and provide patients and consumers with safe, effective and discreet alternatives to smoking, vaporizing or eating cannabis-infused products. The Verra Wellness offering includes the world’s first cannabis nasal mist. The line also consists of a sublingual spray and a topical salve.


Read more on Cannabis Business Executive.

To learn more about the revolutionary Verra Wellness product line, visit: https://verrawellness.com/

24 Oct 2017

MG Retailer: Next Frontier Biosciences Expands Ranks

Word is spreading that Next Frontier Biosciences has hired a new Regional Sales Manager ahead of the company’s upcoming product launch. Recently, the news was shared on MG Retailer, a popular website covering the unprecedented growth of the evolving cannabis industry.


View the full press release on MG Retailer’s website.

16 Oct 2017

Press Release: Next Frontier Biosciences Expands Ranks with New Regional Sales Manager

DENVER (October 11, 2017) – As Next Frontier Biosciences prepares to launch its Verra Wellness line of purified cannabinoid products in November, the Colorado-based biotech company has enhanced its experienced sales lineup with the addition of a new Regional Sales Manager, Colin Osborne.


In preparation for the product launch, Osborne plays a key role in generating a new customer base, forging and fostering strong relationships and educating clients on which products best suit their needs. In addition, he  develops and implements an optimal sales strategy and product promotion while ensuring brand integrity.


Prior to joining Next Frontier Biosciences, Osborne worked in sales for nine years, notably serving as Sales Manager at Weaver Fundraising, LLC. He also served as Enterprise Software Sales Executive at BigMachines, Inc. and Executive Sales Representative at CBLPath, Inc. He later discovered a passion for the cannabis industry as Account Representative and Project Manager at ALl Packaging Company in Aurora, Colorado, and most recently in his role as Retail Associate at The Green Solution in Denver. A former Marine Officer, Osborne earned his bachelor’s degree from Gettysburg College and his master’s degree from Villanova University.


“Colin brings a strong and unique combination of leadership, sales and cannabis industry experience to Next Frontier Biosciences, making him well equipped to lead our regional sales team in introducing Verra Wellness to the market,” said Beth Dresser, Senior Director of Sales and Marketing at Next Frontier Biosciences. “We welcome his insights and know that our clients and staff will benefit from his guidance as we launch the brand in Colorado and establish ourselves as a global cannabis-infused products leader in other markets.”


For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.


About Next Frontier Biosciences: Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, Next Frontier Biosciences is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. Next Frontier Biosciences’ goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.


The company is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., Next Frontier Biosciences’ co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.


Dr. Paul Johnson, Ph.D., Next Frontier Biosciences’ co-founder and Chief Scientific Officer, has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.


Dr. Dorothy “Dot” Colagiovanni, Ph.D., Next Frontier Biosciences’ Vice President of Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen in hematotoxicology.


For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.


# # #